Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)

被引:97
作者
Dupuy, A
Viguier, M
Bédane, C
Cordoliani, F
Blaise, S
Aucouturier, F
Bonnetblanc, JM
Morel, P
Dubertret, L
Bachelez, H
机构
[1] Hop St Louis, Assistance Publ Hop Paris, INSERM, U532,Inst Rech Peau, F-75475 Paris 10, France
[2] Hop St Louis, Assistance Publ Hop Paris, Immunol Lab, Paris, France
[3] Hop St Louis, Assistance Publ Hop Paris, Serv Dermatol 1, Paris, France
[4] Hop St Louis, Assistance Publ Hop Paris, Serv Dermatol 2, Paris, France
[5] Hop Dupuytren, Serv Dermatol, Limoges, France
关键词
D O I
10.1001/archderm.140.1.91
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus vulgaris (PV) is a severe antibody-mediated autoimmune blistering disease. Because some patients with PV do not enter into remission, despite the use of high-dose corticosteroid therapy and immunosuppressive adjuvant treatments, new effective and safer agents are warranted to treat refractory PV. Rituximab, a monoclonal anti-CD20 antibody, induces depletion of B cells in vivo and has shown efficacy in patients with refractory antibody-mediated autoimmune disorders. We describe herein 3 patients treated with rituximab for severe PV. Observations: Three patients with refractory PV were treated with rituximab, resulting in a clinical response in all patients, which was complete in 2 patients. A decline in titers of circulating antiepidermis autoantibodies paralleled disease activity, while circulating B cells remained undetectable for 6 to 10 months. Two patients experienced bacterial infection in the weeks following the rituximab course. A clinical relapse occurred in 2 patients, at 6 and 10 months. A second course of rituximab controlled the disease in one of them. Conclusion: These patients' response suggests that rituximab may be a valuable treatment for refractory PV and warrants further studies to evaluate the risk-benefit ratio in patients with PV showing resistance to classic therapy.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 32 条
[1]   AUTOANTIBODIES AGAINST THE AMINO-TERMINAL CADHERIN-LIKE BINDING DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN ARE PATHOGENIC [J].
AMAGAI, M ;
KARPATI, S ;
PRUSSICK, R ;
KLAUSKOVTUN, V ;
STANLEY, JR .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :919-926
[2]   INDUCTION OF PEMPHIGUS IN NEONATAL MICE BY PASSIVE TRANSFER OF IGG FROM PATIENTS WITH THE DISEASE [J].
ANHALT, GJ ;
LABIB, RS ;
VOORHEES, JJ ;
BEALS, TF ;
DIAZ, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (20) :1189-1196
[3]  
Borradori L, 2001, ARCH DERMATOL, V137, P269
[4]   The adjuvant therapy of pemphigus - An update [J].
Bystryn, JC ;
Steinman, NM .
ARCHIVES OF DERMATOLOGY, 1996, 132 (02) :203-212
[5]   Hematologic malignancies: New developments and future treatments [J].
Cheson, BD .
SEMINARS IN ONCOLOGY, 2002, 29 (04) :33-45
[6]   CHOP plus rituximab - Balancing facts and opinion. [J].
Cheson, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :280-282
[7]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[8]   Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].
Czuczman, MS ;
Grillo-López, AJ ;
White, CA ;
Saleh, M ;
Gordon, L ;
LoBuglio, AF ;
Jonas, C ;
Klippenstein, D ;
Dallaire, B ;
Varns, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276
[9]  
Heizmann M, 2001, AM J HEMATOL, V66, P142, DOI 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO
[10]  
2-0